

## PHARMACY COVERAGE GUIDELINE

### **ACTHAR® GEL (repository corticotropin) injection** **PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection** **Generic Equivalent (if available)**

---

#### **This Pharmacy Coverage Guideline (PCG):**

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

#### **Scope**

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

#### **Instructions & Guidance**

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**

Information about medications that require prior authorization is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy). You must fully complete the request form and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com).

---

## **Medical Necessity Requirements for ACTHAR GEL (repository corticotropin)**

---

### **Criteria for Initial Therapy:**

#### **Prescriber Qualifications**

- Prescribed by a Neurologist or in consultation with a Neurologist

#### **Indication**

- **ONE** of the following:
  - Infantile Epileptic Spasms Syndrome (IESS) without tuberous sclerosis

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### ACTHAR® GEL (repository corticotropin) injection PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection Generic Equivalent (if available)

---

- Acute exacerbation of Multiple Sclerosis (MS)
- Corticosteroid responsive conditions

#### Age Requirement

- **ONE** of the following:
  - Infantile Epileptic Spasms Syndrome (IESS): Less than 2 years of age
  - Multiple Sclerosis (MS): 18 years of age or older
  - Corticosteroid Responsive Conditions: 18 years of age or older

#### Alternative Therapies

- **For Infantile Epileptic Spasms Syndrome (IESS)** without tuberous sclerosis failure (after at least 6 months of use), contraindication per FDA label, or intolerance to corticosteroids that are not expected to occur with use of Acthar Gel
- **For acute exacerbation of multiple sclerosis (MS)** **ALL** of the following:
  - Failure (after at least 6 months of use), contraindication per FDA label, or intolerance to corticosteroids that are not expected to occur with use of Acthar Gel
  - Adherent with maintenance immune suppressing agent for MS
- **For corticosteroid responsive conditions** failure (after at least 6 months of use), contraindication per FDA label, or intolerance to corticosteroids that are not expected to occur with use of Acthar Gel

#### Brand Specific Criteria

- Have failure, contraindication or intolerance with three generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

#### Safety

- There is **NONE** of the following:
  - Intravenous administration
  - Congenital infection suspected in an infant under 2 years
  - Administration of live or attenuated vaccines while on immunosuppressive doses of Acthar Gel
  - History or presence of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

#### Additional Requirements

- Acthar Gel vial is intended for either intramuscular or subcutaneous injection
- Acthar Gel single dose pre filled SelfJect injector is only for subcutaneous administration by adults (18 years of age or older) for administration of either 40 units or 80 units
- For administration of doses other than 40 units or 80 units, use the Acthar Gel multidose vial
- In the treatment of infantile spasms, Acthar Gel must be administered intramuscularly using the Acthar gel vial. The Acthar Gel single dose pre filled SelfJect injector should not be used.

#### Documentation Requirements

- A completed request form must be submitted including:
  - Chart notes

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### ACTHAR® GEL (repository corticotropin) injection PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection Generic Equivalent (if available)

---

- Lab results
- Supporting clinical documentation

#### Initial Therapy Criteria Approval Duration

- 4 weeks OR end of plan year
  - Requests beyond 4 weeks require Medical Director review
  - Maximum of 35 mL (7 vials); requests for more vials require Medical Director review
- 

#### Criteria for Continuation of Therapy (renewal therapy):

**Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.**

#### Prescriber Qualifications

- Continues to be seen by a Neurologist or is in consultation with a Neurologist

#### Clinical Response

- No development of contraindications or significant adverse drug effects including:
  - Infection (viral, bacterial, fungal, protozoan, helminthic)
  - Adrenal insufficiency
  - Cushing's syndrome
  - Gastrointestinal perforation and bleeding
  - Severe behavioral or mood disturbances

#### Adherence

- Adherence to prescribed therapy regimen has been documented

#### Brand Specific Criteria

- Have failure, contraindication or intolerance with three generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

#### Safety

- There is **NONE** of the following:
  - Intravenous administration
  - Congenital infection suspected in an infant under 2 years
  - Administration of live or attenuated vaccines while on immunosuppressive doses of Acthar Gel
  - History or presence of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

#### Additional Requirements

- Acthar Gel vial is intended for either intramuscular or subcutaneous injection
- Acthar Gel single dose prefilled SelfJect injector is only for subcutaneous administration by adults (18 years of age or older) for administration of either 40 units or 80 units
- For administration of doses other than 40 units or 80 units, use the Acthar Gel multidose vial

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### ACTHAR® GEL (repository corticotropin) injection PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection Generic Equivalent (if available)

---

- In the treatment of infantile spasms, Acthar Gel must be administered intramuscularly using the Acthar gel vial. Is not using Acthar Gel single dose prefilled SelfJect injector
- Adherent with maintenance immune suppressing agent for multiple sclerosis (MS)
- Not using Acthar Gel monthly as prophylaxis of acute exacerbations of multiple sclerosis (MS)

#### Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement
- Lab values confirming safe use

#### Continuation Therapy Criteria Approval Duration

- 4 weeks OR end of plan year
  - Requests beyond 4 weeks require Medical Director review
  - Maximum of 35 mL (7 vials); requests for more require Medical Director review
- 

### Medical Necessity Requirements for PURIFIED CORTROPHIN GEL (repository corticotropin)

---

#### Criteria for Initial Therapy:

##### Prescriber Qualifications

- Prescribed by a Neurologist or in consultation with a Neurologist

##### Indication

- **ONE** of the following:
  - Acute exacerbation of Multiple Sclerosis (MS)
  - Corticosteroid responsive conditions

##### Age Requirement

- 18 years of age or older

##### Alternative Therapies

- **For acute exacerbation of multiple sclerosis (MS) ALL** of the following:
  - Failure (after at least 6 months of use), contraindication per FDA label, or intolerance to corticosteroids that are not expected to occur with use of Purified Cortrophin Gel
- **For corticosteroid responsive conditions** failure (after at least 6 months of use), contraindication per FDA label, or intolerance to corticosteroids that are not expected to occur with use of Purified Cortrophin Gel

##### Brand Specific Criteria

## PHARMACY COVERAGE GUIDELINE

### ACTHAR® GEL (repository corticotropin) injection PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection Generic Equivalent (if available)

---

- Have failure, contraindication or intolerance with three generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

#### Safety

- There is **NONE** of the following:
  - Intravenous administration
  - History or presence of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin
  - Primary adrenocortical insufficiency or adrenocortical hyperfunction

#### Documentation Requirements

- A completed request form must be submitted including:
  - Chart notes
  - Lab results
  - Supporting clinical documentation

#### Initial Therapy Criteria Approval Duration

- 4 weeks OR end of plan year
  - Requests beyond 4 weeks require Medical Director review
  - Maximum of 35 mL (7 vials); requests for more require Medical Director review
- 

#### Criteria for Continuation of Therapy (renewal therapy):

**Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.**

#### Prescriber Qualifications

- Continues to be seen by a Neurologist or is in consultation with a Neurologist

#### Clinical Response

- No development of contraindications or significant adverse drug effects

#### Adherence

- Adherence to prescribed therapy regimen has been documented

#### Brand Specific Criteria

- Have failure, contraindication or intolerance with three generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

#### Safety

- There is **NONE** of the following:
  - Intravenous administration

## PHARMACY COVERAGE GUIDELINE

### **ACTHAR® GEL (repository corticotropin) injection** **PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection** **Generic Equivalent (if available)**

---

- History or presence of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin
- Infection
- Adrenal insufficiency
- Cushing's syndrome
- Gastrointestinal perforation and bleeding
- Severe behavioral or mood disturbances

#### **Additional Requirements**

- Adherent with maintenance immune suppressing agent for multiple sclerosis (MS)
- Not using Purified Cortrophin Gel monthly as prophylaxis of acute exacerbations of multiple sclerosis (MS)

#### **Documentation Requirements**

- Chart notes
- Supporting clinical documentation with evidence of improvement
- Lab values confirming safe use

#### **Continuation Therapy Criteria Approval Duration**

- 4 weeks OR end of plan year
  - Requests beyond 4 weeks require Medical Director review
  - Maximum of 35 mL (7 vials); requests for more require Medical Director review
- 

### **Criteria for Off-Label Use Requests:**

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
  2. Off-Label Use of Cancer Medications
- 

#### **Description:**

Repository corticotropin (Acthar Gel, Purified Cortrophin Gel) injection is a preparation of the natural form of adrenocorticotrophic hormone (ACTH) in gelatin to provide a prolonged release after intramuscular or subcutaneous injection. ACTH works by stimulating the adrenal cortex to produce cortisol, corticosterone and a number of other hormones. Repository corticotropin is primarily used for treating infantile spasms, it has been investigated for diagnostic testing of adrenocortical function, and it has been used in the treatment of a variety of other conditions.

## PHARMACY COVERAGE GUIDELINE

### **ACTHAR® GEL (repository corticotropin) injection** **PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection** **Generic Equivalent (if available)**

Repository corticotropin, as Acthar gel, was approved by the U.S. Food and Drug Administration (FDA) in 1952, before there was a requirement that innovator companies provide clinical evidence of efficacy of their product.

Prescription products have a package label that covers important information to guide prescribers on the proper use of the product such as product description, use, available dosage forms, dosing information, administration, contraindications, warnings/precautions, adverse effects, and other safety and efficacy data. The Clinical Studies section of the product label contains a brief review of the clinical study or studies that were presented to the FDA to obtain formal FDA approval.

Acthar Gel product label says that it is indicated for *infantile spasms* and indicated for the treatment of acute exacerbations of multiple sclerosis. The label lists several conditions where it says Acthar Gel may be used. The product label provides specific dosing and administration information for infantile spasms and acute exacerbations of multiple sclerosis and a usual dosage range and frequency for the other uses. The product label states that controlled clinical trials have shown ACTH to be effective in speeding the resolution of acute exacerbations of multiple sclerosis but there is no evidence that it affects the ultimate outcome or natural history of the disease. The clinical studies section of the product labeling of Acthar Gel describes efficacy data only for infantile spasms. Clinical efficacy and safety data for other uses are lacking. There is little data available for the listed general uses for rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, and edematous disorders/diseases. These uses were grandfathered in by the FDA. Based on the lack of both efficacy and safety data for the above referenced grandfathered uses, these additional disorders will be considered unsupported.

Purified Cortrophin Gel product label says it is indicated for conditions where Acthar Gel stated it may be used. The product label also lists other conditions that are not included in Acthar Gel labelling. Purified Cortrophin Gel product label does not have a Clinical Studies section that would provide a summary of the data supporting use for these conditions. The label does not list infantile spasms as a use for the product. The product label provides specific dosing only for acute exacerbations of multiple sclerosis. Under the Precautions – General section it states that controlled clinical trials have shown ACTH to be effective in speeding the resolution of acute exacerbations of multiple sclerosis but there is no evidence that it affects the ultimate outcome or natural history of the disease. The label goes on to recommend a specific dose for acute exacerbations. Given the lack of both efficacy and safety data, use of Purified Cortrophin for other disorders will be considered unsupported except for acute exacerbations of multiple sclerosis.

Although repository corticotropin (Acthar Gel, Purified Cortrophin Gel) can be used to treat various other medical conditions responsive to corticosteroid therapy, it has not been proven to be superior to corticosteroids for these uses. Corticosteroid therapy is generally considered the treatment of choice. Acthar Gel and Purified Cortrophin have limited therapeutic value since they cannot be administered orally, and their effectiveness is dependent on adrenocortical responsiveness. There is a lack of controlled studies on repository corticotropin for treatment of non-corticosteroid-responsive conditions. The adverse effects of both Acthar Gel and Purified Cortrophin Gel are related primarily to steroid-like effects.

Acthar Gel is a naturally sourced complex mixture of adrenocorticotrophic hormone analogs and other pituitary peptides. The manufacturing process converts the initial porcine pituitary extract with low ACTH content into a mixture having modified porcine ACTH and other related peptide analogs solubilized in gelatin. A major component in the formulated complex mixture is N-25 deamidated porcine ACTH (1-39). Acthar Gel is available as a 5 mL vial (80 units/mL, total of 400 units).

## PHARMACY COVERAGE GUIDELINE

### **ACTHAR® GEL (repository corticotropin) injection** **PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection** **Generic Equivalent (if available)**

Purified Cortrophin Gel is a porcine derived purified corticotropin (ACTH) in a sterile solution of gelatin. It is made up of a complex mixture of ACTH, ACTH related peptides and other porcine pituitary derived peptides. It contains the porcine derived ACTH (1-39). Purified Cortrophin Gel is supplied sterile in 5 mL multiple-dose vials containing 80 USP units/mL.

#### **Definitions:**

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting  
[MedWatch Forms for FDA Safety Reporting | FDA](#)

#### **Infantile spasms (also known as infantile epileptic spasms syndrome (IESS)):**

Evidence of specific abnormal pattern detected by a video EEG with hypsarrhythmia

Response is defined as achieved and maintains complete cessation of spasms and elimination of hypsarrhythmia on a full sleep video EEG

#### **MS exacerbation:**

Evidence of an attack with neurologic disturbances consistent with MS developing acutely or sub acutely with a duration of at least 24 hours, with or without recovery, and in the absence of fever or infection

MS exacerbation, relapse, flare, and attack are synonyms. The term "clinically isolated syndrome" (CIS) is also synonymous when used to denote the first clinical episode of MS; a CIS resembles a typical MS relapse but occurs in a patient not known to have MS.

Response is defined as **THREE** of the following:

- Mild/minimal to no functional neurologic (pyramidal, cerebellar, brainstem, sensory) disabilities
- Ambulatory without need for assistance
- Reduction in number of exacerbations or relapses of MS
- Prolonged time to exacerbation or relapses of MS
- Reduction in hospitalizations for MS

#### **Resources:**

Acthar Gel (repository corticotropin) product information, revised by Mallinckrodt ARD, LLC. 02-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed October 27, 2025.

Purified Cortrophin Gel (repository corticotropin) product information, revised by ANI Pharmaceuticals, Inc. 08-2025. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed October 27, 2025.

Takacs DS, Katyaayan A. Infantile epileptic spasms syndrome: Management and prognosis. In: UpToDate, Nordli DR, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through November 2025. Topic last updated December 08, 2025. Accessed December 23, 2025.

Takacs DS, Katyaayan A. Infantile epileptic spasms syndrome: Clinical features and diagnosis. In: UpToDate, Nordli DR, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through November 2025. Topic last updated August 12, 2025. Accessed December 23, 2025.

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

## PHARMACY COVERAGE GUIDELINE

### **ACTHAR® GEL (repository corticotropin) injection** **PURIFIED CORTROPHIN™ GEL (repository corticotropin) injection** **Generic Equivalent (if available)**

---

Takacs DS, Katyayan A. Infantile epileptic spasms syndrome: Etiology and pathogenesis. In: UpToDate, Nordli DR, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through November 2025. Topic last updated September 26, 2025. Accessed December 23, 2025.

Olek MJ, Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. In: UpToDate, Gonzalez-Scarano F, Dashe JF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through November 2025. Topic last updated May 27, 2025. Accessed December 23, 2025.

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE: 02/19/2026

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.